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Alternative mRNA splicing provides transcript diver-
sity and may contribute to human disease. We
demonstrate that expression of several genes regu-
lating RNA processing is decreased in both liver
and skeletal muscle of obese humans. We evaluated
a representative splicing factor, SFRS10, downregu-
lated in both obese human liver and muscle and in
high-fat-fed mice, and determined metabolic impact
of reduced expression. SFRS10-specific siRNA
induces lipogenesis and lipid accumulation in hepa-
tocytes. Moreover, Sfrs10 heterozygous mice have
increased hepatic lipogenic gene expression, VLDL
secretion, and plasma triglycerides. We demonstrate
that LPIN1, a key regulator of lipid metabolism, is
a splicing target of SFRS10; reduced SFRS10 favors
the lipogenic b isoform of LPIN1. Importantly,
LPIN1b-specific siRNA abolished lipogenic effects
of decreased SFRS10 expression. Together, our
results indicate that reduced expression of SFRS10,
as observed in tissues from obese humans, alters
LPIN1 splicing, induces lipogenesis, and therefore
contributes to metabolic phenotypes associated
with obesity.208 Cell Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier IncINTRODUCTIONObesity is a global epidemic, with substantial adverse social,
economic, and personal health consequences. Foremost
among these are the severe metabolic complications of
obesity, including insulin resistance, T2D (type 2 diabetes),
and increased cardiovascular disease risk. While the precise
molecular defects underlying these complications remain
unknown, abnormal lipid metabolism is a consistent phenotype.
Indeed, both hypertriglyceridemia and ectopic lipid accumula-
tion in liver and skeletal muscle are closely linked to both insulin
resistance and diabetes risk (Browning and Horton, 2004;
Jacob et al., 1999; Kotronen et al., 2007). Thus, we aimed to
identify expression signatures of obesity in liver and muscle of
human subjects. We now demonstrate results from two inde-
pendent human cohorts, which both identified decreased
expression of genes regulating RNA processing and splicing
as the top-ranking expression phenotypes in liver and muscle
of obese humans.
RNA processing is a complex cascade including constitutive
and alternative splicing, polyadenylation, and nuclear export of
mature mRNA (Stamm et al., 2005). Alternative splicing occurs
for more than 90% of human genes (Wang et al., 2008) in the
spliceosome, which consists of pre-mRNA, small ribonucleopro-
teins (snRNPs), and two major groups of non-snRNPs, splicing
factors, and heterogeneous ribonucleoproteins (HNRNPs). The
resulting splice variants have a fundamental role in differentiation.
Table 1. Clinical Characteristics of Study Subjects
Liver Study Skeletal Muscle Study
Lean
NGT
Obese
NGT/T2D
Lean
NGT
Obese
IGT/T2D
Men/Women 0/5 2/6 0/10 0/7
Age (years) 36 ± 12 43 ± 11 59.6 ± 5.0 60.0 ± 4.8
Body Mass
Index (kg/m2)
24 ± 5 53 ± 7b 27.4 ± 5.4 31.8 ± 6.5a
Fasting glucose
(mmol/L)
4.8 ± 0.8 6.5 ± 2.0 4.5 ± 0.6 5.0 ± 0.8
Fasting insulin
(pmol/L)
36.8 ± 33.0 148.2 ± 132.6a 40.3 ± 20.2 73.0 ± 23.4a
Subjects had no known abnormality in glucosemetabolism prior to study.
Six obese subjects were diagnosed with type 2 diabetes (T2D) during the
liver study. Four obese subjects were diagnosed with impaired glucose
tolerance (IGT) and three with T2D during the muscle study. Data are
mean ± SD.
a p < 0.05 versus lean of the same study.
b p < 0.001 versus lean of the same study.
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SFRS10 in Human Obesityand organ development (Bland et al., 2010), and tissue-specific
isoforms are commonly observed (Blencowe, 2006; Nilsen and
Graveley, 2010). Thus, alternative splicing should be viewed as
an important adaptive mechanism used to create protein diver-
sity in response to distinct developmental and metabolic cues
(Salomonis et al., 2010; Nilsen and Graveley, 2010). Alternative
splicing can be disrupted in several disease states, including
cancer (Karni et al., 2007; Venables, 2004) and monogenic
human diseases (Faustino and Cooper, 2003). Moreover, several
genes linked to obesity and insulin resistance have been shown
to be regulated by alternative splicing (Kishore and Stamm,
2006; Sesti et al., 1991; Lefai et al., 2001; Patel et al., 2005;
Ghosh et al., 2007; Lee et al., 1996), and defects in RNA process-
ing and nuclear export are associated with lipodystrophy
(Agarwal and Garg, 2006).
Our results now indicate that modification of alternative
splicing may also contribute to metabolic phenotypes associ-
ated with human obesity, as reduced hepatic and muscle
expression of a subset of splicing factors is associated with
obesity, increased hepatic fat content, and hyperinsulinemia.
To investigate whether this downregulation could contribute to
phenotypes associated with obesity, we further studied a repre-
sentative splicing factor, SFRS10, which was downregulated in
both liver and muscle of obese humans. SFRS10 (official gene
name, TRA2B), the homolog of Drosophila transformer-2
(Tra2), belongs to the SR-like protein family of splicing factors,
and is an important modulator of alternative splicing of multiple
genes (Nayler et al., 1998). We demonstrate that reduced
expression of SFRS10 alters splicing of LPIN1, a key regulator
of lipid metabolism (Csaki and Reue, 2010; Pe´terfy et al., 2005;
Yao-Borengasser et al., 2006; Ryu et al., 2009; Huang et al.,
2011), and contributes to increased hepatic lipogenesis and
increased VLDL secretion in mice.
RESULTS
Expression of Genes Regulating mRNA Processing
Is Decreased in Obesity
To identify differentially expressed genes in both liver and
muscle from insulin-resistant humans with obesity, we utilized
high-density oligonucleotide arrays in two independent cohorts
(Table 1). Up- or downregulated probesets common to both
studies are shown in Table S1. GO-based pathway analysis
(MAPPFinder) demonstrated that the top-ranking downregu-
lated pathways in both tissues were related to RNA processing
and splicing (Figure 1A). For example, 46 of 199 RNA splicing
genes were downregulated in liver (Z score 7.5, adjusted
p < 0.001) and 41 of 199 were downregulated in muscle (Z score
11.1, p < 0.001). Gene set enrichment analysis (GSEA) also iden-
tified the RNA-processing gene set as downregulated in obese
subjects in liver (nominal p < 0.001, FDR 0.039), but not in muscle
(nominal p = 0.26, FDR 0.87). Expression of 13 genes involved in
RNA processing and splicing was decreased in both liver and
muscle (Figure 1B). A complete list of genes for each tissue is
shown in Tables S2 and S3.
We next asked whether decreased expression of RNA-pro-
cessing genes is also present in a mouse model of diet-induced
obesity. Indeed, expression of several RNA-processing genes
was decreased following a high-fat diet (HFD) for 4 months inCelboth liver and muscle (Figure 1C). Reduced expression of
SFRS10 and HNRPK was confirmed by western blot in liver of
HFD-fed mice (Figure 1D).
Obesity in both humans and HFD-fed mice is characterized by
alterations in both systemic and cellular glucose and lipidmetab-
olism, which could potentially contribute to the observed down-
regulation of this subset of RNA-processing genes. We therefore
assessed correlation of the 13 genes downregulated in both
tissues with key metabolic phenotypes in humans (Table S4).
Of these, liver expression of nine genes correlated inversely
with obesity, as measured by body mass index (BMI), and five
genes inversely with hepatic lipid content. Skeletal muscle
expression of six genes correlated inversely with fasting insulin.
No correlation between expression and fasting glucose was
observed in either tissue.
We chose SFRS10 as a representative splicing factor for
further analysis, as it was altered most consistently in both
human and animal models. Examination of public databases
indicated that hepatic mRNA expression of Sfrs10 was not
modulated in mice by (a) insulin deficiency (streptozotocin-
induced diabetes) (Yechoor et al., 2002) or (b) experimentally
induced insulin resistance (due to liver-specific deletion of insulin
receptor IRS1, IRS2, or both IRS1 and IRS2) in the absence of
obesity (Guo et al., 2009; Biddinger et al., 2008). Similarly,
muscle-specific insulin resistance, even with superimposed
hyperglycemia, does not alter Sfrs10 expression (Yechoor
et al., 2004). Additionally, exposure of HepG2 hepatoma cells
and C2C12 myotubes to palmitate or elevated glucose did not
affect SFRS10 expression. However, overnight incubation with
10 nM insulin decreased SFRS10 expression (Figure S1), sup-
porting a potential role for chronic insulin exposure in contrib-
uting to decreased SFRS10 expression.Reduced Expression of SFRS10 Leads to Increased
Lipogenesis in Cultured Cells
To assess the functional consequences of decreased splicing
factor gene expression, we experimentally reduced SFRS10l Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier Inc. 209
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Figure 1. RNA-Processing Gene Expression Is Downregulated in Obesity
(A) Top-ranking downregulated pathways in obese humans are identified through GO-based pathway analysis (MAPPFinder) of microarray data from liver and
muscle.
(B) Heatmap of 13 RNA-processing genes with decreased gene expression in both tissues. Blue indicates lower and red higher gene expression. NGT, normal
glucose tolerance; IGT, impaired glucose tolerance; T2D, type 2 diabetes.
(C) Expression of RNA-processing genes was determined by real-time PCR from mouse liver and muscle after 4 months of HFD (black bars) compared to chow
diet (white bars). Data are mean ± SEM. *, p < 0.05 versus chow (n = 6).
(D) Protein levels of SFRS10, SFPQ ,and HNRPK were measured by western blot from liver nuclear extracts. See Figure S1.
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SFRS10 in Human Obesityexpression in HepG2 cells. siRNA-mediated knockdown of
SFRS10 led to a 50%–70% decrease in mRNA and protein
levels (Figure 2A). Given that decreased expression of several
RNA processing genes was associated with increased hepatic
lipid content in human subjects, we examined the effects of
reducing SFRS10 on lipid metabolism in hepatic cells. Indeed,
SFRS10 knockdown in HepG2 cells induced a 1.5- to 2-fold
increase in lipogenic genes, including SREBP1c, FASN,
ACC1, and DGAT2 (Figure 2B). While we observed trends for
SFRS10 knockdown to increase expression of SREBP1a and
PCK1 (PEPCK), expression of other genes influencing lipid or
glucose metabolism, including ESR1 (ERRa), NR1H3 (LXRa),
NR1H2 (LXRb), NR1H4 (FXR), PPARA, PPARG, PPARD,
PPARGC1A (PGC-1a), and PPARGC1B (PGC-1b), did not differ
following SFRS10 knockdown (Table S5). Notably, SFRS10
knockdown-mediated increases in lipogenic gene expression
were accompanied by a 1.6-fold increase in lipogenesis, as
measured by [14C]-acetate incorporation into the lipid fraction
(p < 0.05) (Figure 2C), and led to a 1.4-fold increase in cellular210 Cell Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier Incaccumulation of triglycerides (TAG) (p < 0.05) (Figure 2D).
TAG synthesis from [14C]-palmitate (Figure 2E) or fatty acid
oxidation (Figure 2F) did not differ between control and
SFRS10 knockdown, suggesting TAG accumulation was due
to enhanced fatty acid synthesis. Similar effects of SFRS10
knockdown were observed in C2C12 myotubes; these included
induction of SREBP1c and FASN expression, as well as
increased TAG accumulation (Figure S2). These lipogenic
effects were specific for SFRS10, as knockdown of the consti-
tutive splicing factor SF3A1 had no effect on lipogenic gene
expression or lipid accumulation in either HepG2 or C2C12 cells
(Figure S2).
To determine whether increased Sfrs10 expression could also
modulate lipid metabolism, Hepa1c hepatoma cells were trans-
fected with a DNA construct expressing Sfrs10. As seen in
Figure S3, experimental overexpression of Sfrs10 in Hepa1c
cells significantly decreased expression of the lipogenic genes
Fasn, Agpat2, and Dgat2 (p < 0.05 for SFRS10 versus GFP)
(Figure S3B)..
AC D E
B
F
SCR SFRS10siRNA:
Lipogenesis
c
p
m
 
/
 
μ
g
 
p
r
o
t
e
i
n
*
*
g
 
T
A
G
 
/
 
m
g
 
p
r
o
t
e
i
n
TAG Content
SCR SFRS10siRNA: SCR SFRS10siRNA:
TAG Synthesis
c
p
m
 
/
 
μ
g
 
p
r
o
t
e
i
n
0
200
400
600
800
1000
SCR SFRS10siRNA:
c
p
m
 
/
 
μ
g
 
p
r
o
t
e
i
n
Lipid Oxidation
**
SFRS10 siRNASCR siRNA
*
*
R
e
l
a
t
i
v
e
 
L
e
v
e
l
s
SREBP1c FASN ACC1 DGAT2
mRNA Levels
0
50
100
150
200
250
R
e
l
a
t
i
v
e
 
L
e
v
e
l
s
SCRsiRNA:
Western blot: anti-SFRS10
SFRS10 mRNA
SFRS10
*
Figure 2. SFRS10 Knockdown Increases Expression of Lipogenic Genes and Leads to TAG Accumulation in Hepatic Cells
(A) (All panels) HepG2 cells were transfected with scramble (SCR) or SFRS10 siRNA and analyzed 4 days later. SFRS10 mRNA and protein levels were analyzed
by real-time PCR and Western blot (A).
(B) mRNA levels were determined by real-time PCR.
(C–F) Lipogenesis (from 14C-acetate) (C), TAG levels (D), TAG synthesis (E), and fatty acid oxidation (F) were measured as described in Experimental Procedures.
Data are mean ± SEM of triplicates, representative of three independent experiments. *, p < 0.05 versus SCR siRNA. See Figure S2.
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SFRS10 in Human ObesitySfrs10+/– Mice Have Increased Lipogenic Gene
Expression, VLDL Secretion, and Plasma Triglycerides
We next studied whether decreased expression of Sfrs10
induces hepatic lipogenesis in a mouse model in vivo. For this
purpose, the Sfrs10 locus was disrupted as described in Exper-
imental Procedures. No Sfrs10 / pups were detected, confirm-
ing that genetic disruption of the Sfrs10 gene is lethal during
embryonic life (Mende et al., 2010). However, heterozygous
Sfrs10 +/micewere viable, had normal growth and bodyweight,
and showed no differences in blood glucose and insulin levels
compared to wild-type animals (Figure S4). As shown in Fig-
ure 3A, hepatic Sfrs10 mRNA levels were decreased by 30% in
heterozygous mice compared to wild-type, a magnitude similar
to the decrease in obese humans. Sfrs10 protein levels were
only slightly decreased in the liver of heterozygous mice (Fig-
ure 3A), likely due to the known autoregulation of Sfrs10 protein
mediated by a negative feedback loop (Stoilov et al., 2004).
When present at high levels, Sfrs10 binds to its own exon 2,
activating its inclusion and generating the Tra2b4 isoform that
is not translated into protein. Conversely, low Sfrs10 protein
levels induce exon 2 skipping, favoring the Tra2b1 isoform, the
main functional isoform. In accord with this autoregulation, we
observed an 80% decrease in Tra2b4 mRNA levels in the liver
ofSfrs10 heterozygousmice, with amuch smaller 25%decrease
in Tra2b1 (Figure S4). These data indicate that lower Sfrs10
expression in the heterozygous mice promotes skipping of its
own exon 2 in an attempt to restore protein levels.
Despite this autoregulation, and in agreement with the in vitro
data, Sfrs10 heterozygous mice showed increased hepatic
expression of lipogenic and TAG synthesis genes, including
Srebp1c, Fasn, Scd1, Dgat2, and Agpat2 in the postprandial
state (1.5- to 4.6-fold compared to wild-type, p < 0.05) (Fig-Celure 3B). While liver TAG accumulation remained unchanged (Fig-
ure 3C), plasma TAG levels were 52% higher in the heterozygous
mice (p < 0.05) (Figure 3D). In particular, we observed a marked
increase in plasma levels of the TAG-enriched VLDL fraction
(3-fold, p < 0.05) (Figure 3E), indicating hepatic origin of the
higher plasma TAG. To determine if this pattern was indeed
due to increased hepatic VLDL secretion, we measured plasma
TAG following administration of tyloxapol, an inhibitor of TAG
clearance. Plasma TAG were 2- to 3-fold higher in heterozygous
mice, confirming increased secretion (p < 0.05 at all time points)
(Figure 3F). Together, these data indicate that decreased
expression of Sfrs10 is sufficient to increase hepatic lipogenic
gene expression, increase VLDL secretion, and induce hypertri-
glyceridemia in a mouse model in vivo.
Lpin1 Splicing Is Regulated by Sfrs10
Our data suggest that specific targets of Sfrs10 upstream of
Srebp1c and Fasn may mediate effects on lipid accumulation.
It has been shown that Sfrs10 binds to RNA with the sequence
NGAA. The protein binds to AGAA with an affinity of 2.25 mM
and to GGAA with 4.5 mM (Cle´ry et al., 2011). Therefore, we
considered known genes with alternatively spliced isoforms,
particularly those regulating lipogenesis. Of these, Lpin1 is
known to regulate lipid metabolism (Csaki and Reue, 2010;
Bou Khalil et al., 2010) and has two major alternatively spliced
isoforms, a and b, and a third variant, g, recently identified in
brain (Han and Carman, 2010). The b isoform, generated by
inclusion of exon 6, is associated with increased expression of
lipogenic genes (Pe´terfy et al., 2005; Csaki and Reue, 2010).
Interestingly, the alternatively spliced exon 6 of Lpin1 contains
a GGAA sequence motif that binds to SFRS10, and these
sequences are highly conserved between human LPIN1 andl Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier Inc. 211
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Figure 3. Sfrs10 Heterozygous Mice Show Increased Lipogenic Gene Expression and Hypertriglyceridemia
(A) (All panels) Wild-type (WT) and Sfrs10 heterozygous (Het) mice were fasted for 16 hr and then refed for 10 hr before sacrifice. Liver Sfrs10 mRNA and protein
levels were determined by real-time PCR and western blot (A).
(B) Liver mRNA was quantified by real-time PCR.
(C and D) Liver TAG (C) and plasma TAG (D) were measured as in Experimental Procedures.
(E) Plasma lipoprotein profile was determined by FPLC.
(F) VLDL secretion was calculated by quantifying plasma TAG after Tyloxapol administration. Data are mean ± SEM of at least five mice/group and are repre-
sentative of two independent cohorts. *, p < 0.05 versus WT. See Figure S4.
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SFRS10 in Human Obesitymouse Lpin1 genes (Figure 4A). The location of the Sfrs10 site is
unusual, as it partially overlaps with the U1 binding sites at the
50 splice site. To determine if alterations in SFRS10 expression
could indeed modulate splicing of LPIN1, we used a minigene
construct containing the alternative exon 6 of the human LPIN1
gene. Cotransfection of the minigene construct with a plasmid
expressing SFRS10 caused exon 6 skipping (Figure 4B, left).
Conversely, SFRS10 siRNA increased inclusion of exon 6 (Fig-
ure 4B, right). These findings suggest that SFRS10 competes
with U1 snRNA for binding at the 50 splice site. With higher
SFRS10 expression, U1 snRNA could be replaced by SFRS10,
leading to exon skipping; with lower SFRS10 expression, U1
snRNA could bind the 50 splice site and thus initiate exon
inclusion.
We next assessed whether SFRS10 knockdown affected
splicing of endogenous LPIN1 in HepG2 cells. Notably,
SFRS10 siRNA did not change total LPIN1 expression (Fig-
ure S5), but altered the generation of LPIN1 splice isoforms,
yielding an increase in the b isoform in parallel with a modest
decrease in the a isoform (Figure 4C, left). As a result, the ratio
of the endogenous b isoform in relation to the a isoform
(LPIN1b/a ratio) increased in response to SFRS10 knockdown
(Figure 4C, right), confirming that modified SFRS10 expression
leads to alteredLPIN1 splicing. A similar increase inLpin1b/a ratio
was observed in response to Sfrs10 knockdown in C2C12
myotubes (Figure S2). This effect was specific to SFRS10,
since knockdown of the constitutive splicing factor SF3A1
did not alter LPIN1 splicing, as indicated by unchanged212 Cell Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier IncLPIN1b/a ratio (Figure S2). Similar results were observed in liver
of Sfrs10 heterozygous mice: no change in total Lpin1 expres-
sion (Figure 4D, left), but an increase in the Lpin1b/a ratio (Fig-
ure 4D, right). Consistent with this effect, and in parallel with
reduced SFRS10 levels, we also observed a significant increase
in the Lpin1b/a ratio in liver of HFD-fed mice (Figure 4E) and a
similar trend in liver of obese humans (Figure 4F). Conversely,
overexpression of Sfrs10 in Hepa1c cells reduced the Lpin1b/a
ratio as compared to GFP control (Figure 4G). Together, these
results indicate that SFRS10 levels can modulate LPIN1 splicing
and, thus, ratios between the b and a isoforms of LPIN1.
Lipin1 protein was initially identified as a type 1 phosphatidic
acid phosphatase (PAP-1) acting in the TAG synthesis pathway
(Han et al., 2006; Donkor et al., 2007), but also subsequently
recognized as a transcriptional regulator of lipid metabolism
(Finck et al., 2006). LPIN1b induces lipogenic gene expression
in adipocytes (Pe´terfy et al., 2005). Indeed, Sfrs10 downregula-
tion leads to increased expression of lipogenic genes in hepa-
toma cells (Figure 2B), C2C12 myotubes (Figure S2A), and in
Sfrs10 heterozygous mice (Figure 3B). However, we found no
differences in hepatic PAP-1 activity (Figure S4) in heterozygous
mice, as compared to wild-type mice, or in TAG synthesis from
palmitate in cells (Figure 2E).
To investigate if the effects of SFRS10 knockdown on lipo-
genic gene expression were mediated by increases in the
LPIN1b isoform, we developed distinct siRNA oligonucleotides
directed against either total LPIN1 or specifically targeting
exon 6, the LPIN1b-specific exon (Table S6). While total LPIN1.
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Figure 4. SFRS10 Regulates LPIN1 Splicing
(A) The putative binding site of SFRS10, GGAA, is highlighted in gray within alternatively spliced exon 6 sequence (Ensembl release 61) of human and mouse
LPIN1. The U1 snRNA binding site at the 50 splice site is underlined.
(B) SFRS10 cotransfection increases exclusion of LPIN1 exon 6 in a minigene system (left), while SFRS10 siRNA increases inclusion (right). PCR primers are
shown as arrows.
(C and D) Expression of total LPIN1, LPIN1b , and LPIN1a isoforms was determined (real-time PCR) in: HepG2 cells after SCR (white bars) or SFRS10 siRNA
(black bars) (C), and liver samples from WT (white, n = 7) and Sfrs10 heterozygous (black, n = 5) mice (D).
(E–G) Expression of Lpin1b relative to Lpin1awasmeasured by real-time PCR in liver from: HFD (black, n = 6) and chow (white, n = 6) mice (E), lean (white, n = 6) or
obese (black, n = 14) humans (F), and Hepa1c cells after GFP (white, n = 5) or SFRS10 (black, n = 5) overexpression (G). Data are mean ± SEM. *, p < 0.05 versus
control. See Figure S2.
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SFRS10 in Human ObesitysiRNA decreased both LPIN1a and b isoforms, the LPIN1b-
targeted siRNA decreased LPIN1b expression by 68% without
affecting LPIN1a expression, demonstrating specificity of the
LPIN1b siRNA (Figures 5A and S5). Isolated knockdown of either
total or the b-specific isoform of LPIN1 had no significant effects
on FASN expression. However, when SFRS10 expression was
also reduced (via cotransfection with SFRS10 siRNA), the
LPIN1b-specific siRNA abolished SFRS10-mediated increases
in genes regulating fatty acid synthesis and TAG synthesis (Fig-
ure 5A). Importantly, LPIN1b knockdown also prevented the
SFRS10 siRNA-induced increase in lipogenesis (Figure 5B) and
TAG accumulation (Figure 5C) and prevented increases in
lysophosphatidic acid (LPA), an intermediate in the TAG
synthesis pathway (Figure 5D). These findings indicate that
effects of reduced SFRS10 on LPIN1 splicing, favoring the
LPIN1b isoform, are sufficient to increase expression of lipogenic
genes and activate lipogenesis.
DISCUSSION
In the current study, we demonstrate downregulation of a subset
of RNA processing genes in liver and skeletal muscle of obese
humans. Expression of several splicing factors was inversely
related to BMI, hepatic lipid accumulation, and hyperinsulinemiaCelin humans. Moreover, diet-induced obesity reduced expres-
sion of several RNA-processing genes in mice, and exposure
of cultured hepatoma cells to insulin reduced expression of
SFRS10, suggesting a potential role for obesity-linked insulin
resistance and/or chronic hyperinsulinemia in vivo. Additional
factors, including genetic variation, could potentially contribute
to obesity-associated differences in expression regulation. In
particular, a polymorphism close to the SFRS10 locus has
been associated with obesity in several populations (Thorleifs-
son et al., 2009; Cheung et al., 2010).
To examine whether decreased expression of these splicing
factors wasmerely a consequence of or could directly contribute
to obesity-related metabolic phenotypes, wemodulated expres-
sion of a representative alternative splicing factor, SFRS10,
selected due to its consistent downregulation in both human
and rodent tissues. Using both siRNA in cultured cells and in
an in vivo mouse model of Sfrs10 heterozygosity induced by
gene targeting, we observed that experimental reduction in
Sfrs10 expression led to increased lipogenesis, likely mediated
by upregulation of key lipogenic genes such as Fasn and
Srebp1c. Moreover, we show that heterozygosity for Sfrs10
increases VLDL secretion, resulting in marked hypertriglyceride-
mia in vivo—thus indicating that downregulation of SFRS10 can
indeed contribute to disordered lipid metabolism.l Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier Inc. 213
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SFRS10 in Human ObesityIn this study, we identify Lpin1 as a key splicing target of
Sfrs10, which mediates its effects on lipogenesis. Originally,
a Lpin1 null mutation was discovered as a cause for lipodystro-
phy in mice (Pe´terfy et al., 2001); mutations in LPIN1 in humans
have been linked to abnormal lipid accumulation in muscle
(Zeharia et al., 2008). Subsequent studies identified Lpin1 as
both a phosphatidate phosphatase in the TAG synthesis path-
way and also a transcriptional coactivator of PPARa (Finck
et al., 2006; Csaki and Reue, 2010). Conversely, overexpression
of Lpin1 in either fat or muscle leads to obesity, with additional
metabolic effects depending on tissue site of overexpression
(Phan and Reue, 2005). In humans, transcriptional regulation of
Lpin1 alone is unlikely to explain hepatic lipid accumulation in
obesity, as total Lpin1 expression is reduced in parallel with
insulin resistance in adipose tissue and liver (Croce et al.,
2007; Donkor et al., 2008; Suviolahti et al., 2006; Yao-Boren-
gasser et al., 2006) .
Alternatively spliced isoforms of LPIN1, including a and b, have
distinct patterns of cellular localization and regulation (Pe´terfy
et al., 2005; Bou Khalil et al., 2009; Han and Carman, 2010). For
example, hepatic LPIN1a and b expression in humans does not
correlate in individual subjects, indicating independent isoform
regulation (Croce et al., 2007). The b isoform is associated with
increasedexpression of lipogenic genes in adipose tissue (Pe´terfy
et al., 2005) and has more prominent effects than the a isoform in
promoting TAG secretion in hepatoma cells (Bou Khalil et al.,
2009). By contrast, adenoviral expression of Lpin1b in primary
hepatocytes modestly reduces TAG secretion (Chen et al.,
2008). Furthermore, Lpin1 isoforms have been shown to form
homo- and hetero-oligomers (Liu et al., 2010). Thus, regulation
of Lpin1 expression, isoform splicing, and function is complex,
and precise molecular mechanisms mediating these effects may
be tissue-specific (Phan and Reue, 2005) and differ in fed/fasting
transitions andbetweencellular andanimalmodels. However, our
studies using the Lpin1 exon 6minigene indicate that both knock-
down and overexpression of Sfrs10 alter Lpin1 splicing, indepen-
dently of Lpin1 transcriptional regulation. Moreover, effects of214 Cell Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier Inc.reducedSfrs10expression inpromoting lipogen-
esis are dependent upon the Lpin1b isoform.
Thus, we propose a model in which reduced
expression and splicing activity of Sfrs10 alters
Lpin1 splicing, favoring generation of the Lpin1b
isoform and contributing to lipid synthesis and
hypertriglyceridemia (Figure 6).
We have considered several possible mecha-
nisms by which Lpin1b-dependent effects ofreduced Sfrs10 expression could enhance lipogenesis and
VLDL secretion. First, lipin1 has PAP-1 activity, yielding diacyl-
glycerol (DAG) and thus promoting TAG synthesis (Donkor
et al., 2007). However, we observed no change in TAG synthesis
from labeled palmitate in HepG2 cells with Sfrs10 knockdown,
and there were no differences in PAP-1 activity, nor in phospha-
tidic acid or DAG content (data not shown), in liver from Sfrs10
heterozygous versus wild-type mice. These data likely reflect
the normal mRNA expression of Lpin1, 2, and 3 in the setting
of reduced Sfrs10 expression. While we recognize that activity
assays and staticmeasures of PA andDAGdo not assess poten-
tial increases in flux through the PA-DAG pathway, these data
indicate that effects of Sfrs10 in promoting lipogenesis and
hepatic VLDL secretion are unlikely to bemediated via increased
lipin1-dependent PAP-1 activity.
A second mechanism potentially contributing to lipin1b-de-
pendent effects on lipogenesis is its role as transcriptional coac-
tivator. Lpin1 overexpression in liver and adipose increases
expression of genes modulating lipid oxidation (Finck et al.,
2006; Donkor et al., 2008), potentially via interactions with
PGC-1a and PPARa. In the context of Sfrs10 reductions,
Lpin1b effects on lipid oxidation are not observed. Rather,
increased lipogenesis appears to be the dominant mechanism
mediating TAG accumulation in HepG2 cells, as evidenced
by LPIN1b-dependent increases in lipogenic gene expression
and increased synthesis of TAG from acetate in response to
SFRS10 knockdown. We did not observe increased TAG secre-
tion into the medium in HepG2 cells (data not shown), possibly
reflecting the impaired capacity of HepG2 cells to secrete
TAG, compared to hepatocytes in vivo (Gibbons et al., 1994).
However, the prominent effects of Sfrs10 on lipogenesis were
confirmed in vivo, as demonstrated by the striking increases in
lipogenic gene expression and parallel increases in TAG secre-
tion and plasma VLDL-TAG in Sfrs10 heterozygous mice. Our
data support a role for differential transcriptional effects of the
b versus a splice variants. While we do not yet fully understand
mechanisms responsible for these effects, these splice variants
Lipogenic Genes
Lipogenesis
Other Splicing 
Targets
SFRS10
LPIN1β/α
Figure 6. Human Obesity Is Associated with Decreased Expression
of RNA-Processing Genes and Can Influence Metabolic Phenotypes
Reduced expression of the splicing factor SFRS10 alters splicing of LPIN1,
leading to dysregulation of lipogenic pathways and contributing to hyper-
triglyceridemia. Other alterations in RNA processing in human obesity should
be identified (dashed arrows).
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SFRS10 in Human Obesityhave differential cellular localization (Pe´terfy et al., 2005); the
Lpin1b polybasic motif may play a particularly important role in
nuclear localization and regulation of gene expression, again
independently of PAP-1 activity (Ren et al., 2010). Emerging
data highlight the complexity of this system, as subcellular local-
ization of Lipin1b in turn may be regulated by local phospho-
lipase activity (Huang et al., 2011).
We recognize that general dysregulation of RNA-processing
gene expression, as observed in our obese and insulin-resistant
human cohorts, may have an impact on a broad range of cellular
pathways and that we have focused solely on effects of SFRS10
as a representative gene (Zhong et al., 2009). Furthermore,
LPIN1 is most likely just one of multiple potential splicing targets
of SFRS10. In fact, numerous exons have the NGAA sequence
that can serve as an SFRS10 binding site (Cle´ry et al., 2011).
Identification of additional alternative splicing events mediated
by SFRS10 and, more broadly, in human obesity, may provide
targets that contribute to obesity or insulin resistance-associ-
ated phenotypes.
Additional mechanisms may also contribute to dysregulated
expression and function of genes regulating mRNA splicing/pro-
cessing in human obesity. For example, insulin may also regulate
SFRS10 expression, as overexpression of constitutively active
Fox01 (resistant to nuclear exclusion by insulin) in liver increases
expression of Sfrs10 (Zhang et al., 2006). Furthermore, activation
of Cdc2-like kinase family proteins (Clk) (Jiang et al., 2009) by
insulin may alter phosphorylation and activity of splicing factors,
including SFRS10 (Stoilov et al., 2004). Future studies are
warranted to explore the potential interactions between insulin
signaling, regulation of Clk kinases, and SFRS10.
In summary, we have now identified RNA-processing genes as
a group of genes linked to human obesity. Using the SFRS10-
LPIN1 cascade as an example, we demonstrate that altered
expression and splicing function of SFRS10 may modulate
metabolic pathways critical for obesity and related metabolic
phenotypes. These findings have several implications. First,
genes and molecules regulating mRNA processing should beCelinvestigated as potential candidates in obesity and insulin-resis-
tant states. Second, alternatively spliced isoforms of known
metabolic genes should be identified and characterized, as their
alternative splicing may serve as an important regulatory step.
A recent publication suggests sequence polymorphisms associ-
ated with obesity may also facilitate alternative splicing of
obesity genes (Goren et al., 2008). Moreover, identification of
pathways regulating alternative splicing in obesity may have
implications for other chronic diseases linking with insulin
resistance, as suggested for SFRS10 in Alzheimer’s disease
(Glatz et al., 2006). Finally, our study suggests that modulation
of splicing factors and alternative splicing may be a potential
therapeutic target for obesity-associated tissue lipid accumula-
tion and consequent metabolic complications.
EXPERIMENTAL PROCEDURES
Human Subjects and Tissue Biopsies
Biopsies were obtained from two independent human cohorts: Boston (liver)
and Finland (muscle). For the liver cohort, intraoperative biopsies were
obtained from lean nondiabetic control subjects undergoing cholecystectomy
(n = 5) and from obese subjects undergoing gastric bypass surgery (n = 8).
Although these subjects had no known history of impaired glucose tolerance
(IGT) or T2D, four of the obese subjects were diagnosed with T2D within
1 week prior to gastric bypass, on the basis of oral glucose tolerance testing
(National Diabetes Data Group criteria [1979]). For LPIN1b/a ratio determina-
tion (Figure 4F), additional liver samples were obtained from subjects with
similar metabolic profiles (Pihlajamaki et al., 2009). The muscle cohort
consisted of 17 postmenopausal Caucasian women of Finnish ancestry who
required cholecystectomy. Muscle biopsies (rectus abdominis) were obtained
during abdominal surgery from lean postmenopausal women with normal
glucose tolerance (NGT) (n = 10) or obese women who were diagnosed with
IGT (n = 4) or T2D (n = 3) during the study. All subjects had normal liver, kidney,
and thyroid function, no history of excessive alcohol intake, and no major
chronic illness. All samples were washed with phosphate-buffered saline,
immediately frozen in liquid nitrogen, and stored at 80C.
Informed consent was obtained from all subjects after the purpose and
potential risks of the study were explained. All human studies were performed
in accord with the Helsinki Declaration and were approved by local institutional
review, including by the Institutional Review Boards of the Joslin Diabetes
Center and Beth Israel Deaconess Medical Center and the Ethics Committee
of the Kuopio University Hospital.
Analytical Methods in Human Studies
Plasma glucose was measured using the glucose oxidase method (2300
STAT Plus, Yellow Springs Instrument Co. Inc., Yellow Springs, OH). Plasma
insulin concentration was determined by radioimmunoassay (RIA, Diagnostic
Systems Laboratories, Webster, TX) or commercial double-antibody solid-
phase radioimmunoassay (Insulin RIA 100, Pharmacia Diagnostics AB,
Uppsala, Sweden). Liver fat content was quantified from hematoxylin and
eosin-stained sections (Pihlajamaki et al., 2009).
Animal Care and Treatment
All protocols were approved by the Joslin Institutional Animal Care and Use
Committee. Mice were housed four per cage in an OLAW-certified animal
facility, with 12 hr light cycles. For HFD experiments, 6-week-old ICR mice
were placed on chow (17% calories from fat) or HFD (42% calories from milk-
fat, Harlan Teklad) for 4 months.
Sfrs10 Mouse Generation and Analysis
Mice with heterozygous gene trap insertion at the Sfrs10 locus
(Tra2bGt(P142D08)Wrst) were generated using a mouse embryonic stem cell
line (ID 3SP142D08, http://www.genetrap.org/cgi-bin/annotation.py?cellline=
3SP142D08) containing a Rosabetageo vector inserted in intron 1 of the
Sfrs10 gene. Mice were generated by blastocyst injection and transferred tol Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier Inc. 215
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crossed with C57BL/6J mice. Genotyping was performed by PCR using tail
DNA and two different primer pairs, one flanking the insertion site and the other
recognizing the neo gene in the inserted sequence (available upon request).
For plasma and tissue analysis, 8- to10-week-old males were fasted overnight
and refed ad libitum for 10 hr. Blood glucose was measured using a Bayer
Contour glucometer and insulin levels determined by ELISA (Crystal Chem
Inc.). Mice were anesthetized with pentobarbital prior to tissue harvest.
Cell Culture
Human HepG2 cells, mouse Hepa1c cells, and mouse C2C12myoblasts were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (HepG2 and Hepa1c) or 20% fetal bovine serum
(C2C12). To initiate differentiation, confluent C2C12 cells were incubated in
DMEM containing 2% horse serum (Invitrogen). Full differentiation was
observed by day five. For fatty acid incubations, palmitate (Alltech) was com-
plexed with BSA, yielding a final stock of 5 mM.
RNA Isolation and Expression Analysis
Total RNAwas isolated from human andmouse tissues with TRIzol (Invitrogen)
and from HepG2 and C2C12 cells using RNeasy with DNase I treatment
(QIAGEN). cDNA was synthesized and analyzed by real-time PCR (ABI
Prism 7000 or 7700 Sequence Detection System, Applied Biosystems), using
SYBR Green (cell/mouse) or TaqMan predesigned Assays-on-Demand
(human). Primer sequences are available upon request.
For microarray analysis, 15 mg of cRNAwere hybridized to human Affymetrix
GeneChip HG-U133A arrays. Target preparation, hybridization, and scanning
were performed in Joslin Diabetes Center Genomics Core (liver) or Turku
Centre for Biotechnology (muscle). Signal intensities were quantitated using
GeneChip Operating Software (GCOS). Global scaling was used to stan-
dardize signal intensities. MAPPFinder (www.genmapp.org) and GSEA
(www.broad.mit.edu/gsea) were used to identify differentially expressed
pathways and gene sets (Subramanian et al., 2005). For correlation analyses,
Pearson correlations and associated p values for each probe set were calcu-
lated by comparison with permuted data (R version 2.0.1).
Protein Isolation and Western Blotting
Mouse liver or cultured cells were homogenized in buffer containing protease
inhibitors (Sigma), sodium fluoride (100 mM), sodium orthovanadate (2 mM)
and 1% Triton X-100. Protein concentrations were determined using BCA
assay (Pierce, Rockford, IL). Proteins were separated by SDS-PAGE for sub-
sequent western blotting. Anti-SFRS10 antibody (S4070) was obtained from
Sigma, and anti-SFPQ (ab11825) and anti-HNRPK antibodies (ab18195) from
Abcam (Cambridge, MA).
siRNA of SFRS10, SF3A1, LPIN1, and LPIN1b Isoforms
HepG2 cells were transfected at 20%–40% confluency, and C2C12myotubes
were transfected on differentiation day three with 100 nM SFRS10, SF3A1, or
LPIN1 SMARTpool siRNA or siCONTROL nontargeting siRNA. DharmaFECT 3
(C2C12) or 4 (HepG2) transfection reagent was used (Dharmacon, Lafayette,
CO). We designed three siRNAs specifically targeting exon 6 of LPIN1
(Ensembl release 61, February 2011). The most specific and efficient siRNA
targeting sequence, AAGAACUAGACAGACCUCCUU, was used for subse-
quent studies. To study siRNA knockdown effects on lipogenesis and lipid
accumulation, cells were treated overnight with 1% BSA or 1% BSA/500 mM
palmitate. Efficiency of transfection (>70%–80%; data not shown) was deter-
mined using siGLO RISC-Free nontargeting siRNA (Dharmacon).
DNA Constructs and Transfection
The mouse Sfrs10 cDNA (ATCC, Manassas, VA) was cloned into the
pAdTrack-CMV vector, containing GFP as tracer. Hepa1c cells were tran-
siently transfected using PolyFect (QIAGEN, ratio 3:1 DNA/Polyfect) with either
pAdTrack-Sfrs10 or pAdTrack-CMV (control) plasmids. To enrich for Sfrs10-
expressing cells, GFP-positive cells were selected through FACS (Flow
Cytometry Core, Joslin) and mRNA analyzed from >100,000 GFP-positive
cells.216 Cell Metabolism 14, 208–218, August 3, 2011 ª2011 Elsevier IncIn vivo Cellular Splicing Assay
The minigene was constructed using a fragment of human LPIN1 exon 6,
flanked by 500 nt intronic regions, which was cloned into an exon trap vector
(Stoss et al., 1999). Effects of SFRS10 on inclusion of LPIN1 exon 6were inves-
tigated by transfecting 1 ug of LPIN1 exon 6 minigene into two cell models: (a)
HepG2 cells (Mirus transfection reagent, Madison, WI) 2 days after SFRS10
siRNA transfection (as above), and (b) HEK293 cells, together with SFRS10,
using calcium phosphate. Cells were harvested the next day, and RNA was
extracted (QIAGEN, Valencia, CA). cDNA was created using plasmid-specific
primers, and PCR was done using minigene-specific primers flanking LPIN1
exon 6.
Lipogenesis, TAG Synthesis and Accumulation, Palmitate Oxidation,
PAP-1 Assay, Plasma Lipoprotein Profile, and VLDL Secretion
[14C]-acetate (13 mM, 1 mCi/6-well plate, lipogenesis) or [14C]-palmitate
(50 nM, 5 mCi/6 well plate, TAG synthesis) was added to the media for 2 hr
on day four after siRNA transfection. Cells were lysed as described above,
and lipids were extracted with chloroform/methanol. Lipogenesis was
assessed by measuring radioactivity in the lipid fraction. Thin-layer chroma-
tography (TLC) with Silica Gel G plates (Analtech, Newark, DE) and hexane/
diethyl ether/acetic acid (70/29/1) as a solvent was used to separate fractions.
Incorporation of [14C]-palmitate into the TAG fraction of conditioned medium
was performed by lipid extraction and TLC separation of lipid classes (see
above). To assess palmitate oxidation, cells were pretreated for 4 hr with
125 mM palmitate, followed by addition of [14C]-palmitate (100 mM, 1 mCi/12-
well plate); released CO2 was trapped in 0.1 N KOH for 2 hr.
Mg+2-dependent PAP-1 activity was assessed in Triton X-100 extracts from
wild-type or SFRS10 heterozygous mice after an overnight fast and refeeding
for 10 hr (Ren et al., 2010).
To measure TAG content from cells or liver tissue, lipids were extracted with
chloroform/methanol, and total TAG content was determined using Triglyc-
eride Assay Kit (Sigma). LPA levels were measured from flash-frozen cell
pellets by mass spectrometry (Xiao et al., 2000). Plasma lipoprotein profile
was determined by FPLC (Vanderbilt Diabetes Research and Training Center
lipid core).
To measure VLDL secretion, mice were fasted overnight and refed for 2 hr.
Mice were then fasted for 4 hr before intraperitoneal administration of Tyloxa-
pol (Sigma) at a dose of 500 mg/kg. Tail vein blood samples were obtained
before injection (time 0) and at 90 and 180 min for measurement of TAG
(Sigma).
Statistical Analysis
Data analysis was performed with the SPSS/Win programs (version 10.0,
SPSS Inc., Chicago, IL). A p value of <0.05 was considered statistically signif-
icant. Data are presented as mean ± SEM.
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